PRAP1 and colorectal carcinoma: In contrast, PRAP1 was more advanced in cisplatin-resistant human CRC cells (HCT-116/DDP and HT-29/DDP) and 5-Fluorouracil (5-Fu)-resistant human CRC cells (HCT-116/5-Fu) than in normal HCT-116 cells (P<0.0001; P<0.0001) and HT29 cells (P=0.0011) (Fig. 1D).